Format
Sealed research vial
Trust signal
COA-backed inventory
99%+ Purity
Lab-grade supply. Limited AU stock.
A$319
Select options below
Size
Select one
Select your preferred options to continue.
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
Survodutide is a GLP-1R/GcgR dual agonist (BI 456906) with a C18 fatty diacid conjugate enabling extended albumin-bound half-life in pharmacokinetic models.
Balanced GLP-1R/GcgR agonism is mechanistically interesting because glucagon and GLP-1 produce near-opposite effects on hepatic glucose output in isolated hepatocyte models, yet co-activation of both receptors in vivo produces complex outcomes not predictable from single-receptor data alone. Survodutide provides a balanced-agonism reference to benchmark against GLP-1-biased analogs.
Browse Inventory
In research literature, Survodutide is generally treated as a GLP-1R/GcgR dual agonist (BI 456906) with a C18 fatty diacid conjugate enabling extended albumin-bound half-life in pharmacokinetic models. Survodutide co-activates GLP-1R and GcgR with near-balanced potency — a different pharmacological profile from the GLP-1-biased mazdutide — resulting in more equivalent Gs-cAMP contributions from both receptor pathways in co-expression systems. Its C18 fatty diacid conjugate supports once-weekly pharmacokinetic modelling analogous to semaglutide, enabling half-life comparisons across fatty acid chain length and conjugation site in albumin-binding assays.
Balanced GLP-1R/GcgR agonism is mechanistically interesting because glucagon and GLP-1 produce near-opposite effects on hepatic glucose output in isolated hepatocyte models, yet co-activation of both receptors in vivo produces complex outcomes not predictable from single-receptor data alone. Survodutide provides a balanced-agonism reference to benchmark against GLP-1-biased analogs. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Survodutide behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for Survodutide should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for Survodutide is:
If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare Survodutide with Klow, BPC-157 + TB-500, and Glow, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
It brings together 2 labelled variants: 5mg and 10mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
Survodutide is generally discussed as a GLP-1R/GcgR dual agonist (BI 456906) with a C18 fatty diacid conjugate enabling extended albumin-bound half-life in pharmacokinetic models. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
This page links the broader COA library when a product-specific document is not attached. Laboratories should use the published documentation set that is currently available for the listing.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
